AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37034329 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter tricuspid valve replacement (TTVR) with LuX-Valve guided by 3D printing
Number of subjects: 6
Study 37034344 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C <1.8 mmol/L
Number of subjects: 459
Study 37034344 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C 1.8-<2.6 mmol/L
Number of subjects: 459
Study 37034344 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C ≥2.6 mmol/L
Number of subjects: 459
Study 37034478 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic lifestyle modification program (diet and exercise modification, behavioral support, and Commercial Weight Management Organizations)
Number of subjects: 340
Study 37034478 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 340
Study 37034568 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived individual, interpersonal, and environmental factors influencing weight management
Number of subjects: 23
Study 37034617 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ3370 (SQL70 biopolymer + SQP33 protodrug)
Number of subjects: 0
Study 37034685 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib (AG-120), an FDA-approved mutant IDH1 inhibitor, used as a wtIDH1 inhibitor under nutrient-deprived conditions.
Number of subjects: 0
Study 37034685 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (specific agents not mentioned), which induces expression of wtIDH1.
Number of subjects: 0
Study 37035316 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-SPECT/CT
Number of subjects: 109
Study 37035316 — intervention group
Group type: COMPARATOR
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 109
Study 37035316 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment (SMT)
Number of subjects: 109
Study 37035340 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepackaged low-residue diet (formula LRD)
Number of subjects: 550
Study 37035340 — intervention group
Group type: COMPARATOR
Intervention: Self-prepared low-residue diet (LRD)
Number of subjects: 550
Study 37035409 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab-Emtansine and Osimertinib
Number of subjects: 27
Study 37035457 — intervention group
Group type: EXPERIMENTAL
Intervention: Low complement C3c levels
Number of subjects: 245
Study 37035457 — intervention group
Group type: EXPERIMENTAL
Intervention: High IgG-1 levels
Number of subjects: 245
Study 37035457 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement levels and immunoglobulins
Number of subjects: 245
Study 37035457 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple blood tests
Number of subjects: 245
Study 37035740 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV9 gene therapy, early postnatal administration
Number of subjects: 0
Study 37035920 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC)
Number of subjects: 95
Study 37035920 — intervention group
Group type: COMPARATOR
Intervention: Sham Remote Ischemic Conditioning (sham RIC)
Number of subjects: 95
Study 37035970 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37035978 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Number of subjects: 0
Study 37036035 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive SBP lowering (target, 110 to <130 mmHg)
Number of subjects: 5601
Study 37036035 — intervention group
Group type: COMPARATOR
Intervention: Standard SBP lowering (target, 130 to <150 mmHg)
Number of subjects: 5601
Study 37036035 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive SBP lowering
Number of subjects: 5601
Study 37036035 — intervention group
Group type: COMPARATOR
Intervention: Standard SBP lowering
Number of subjects: 5601
Study 37036062 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon communication during consultations
Number of subjects: 169
Study 37036062 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon communication patterns
Number of subjects: 169
Study 37036102 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondipping blood pressure pattern
Number of subjects: 0
Study 37036102 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondipping blood pressure pattern in patients with carotid artery disease
Number of subjects: 0
Study 37036102 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondipping blood pressure pattern in patients with lower-extremity PVD
Number of subjects: 0
Study 37036134 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramagnetic rim lesions (PRLs) co-localized with slowly expanding lesions (SELs)
Number of subjects: 41
Study 37036134 — intervention group
Group type: EXPERIMENTAL
Intervention: Slowly expanding lesions (SELs)
Number of subjects: 41
Study 37036134 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic MS lesions identified as both PRL and SEL
Number of subjects: 41
Study 37036155 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 150-mg capsule (test)
Number of subjects: 36
Study 37036155 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole 150-mg capsule (reference)
Number of subjects: 36
Study 37036183 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 1227
Study 37036183 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Number of subjects: 1227
Study 37036183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1227
Study 37036404 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-dose HAV vaccine
Number of subjects: 153
Study 37036404 — intervention group
Group type: COMPARATOR
Intervention: 2-dose HAV vaccine administered 4 weeks apart
Number of subjects: 153
Study 37036404 — intervention group
Group type: COMPARATOR
Intervention: 2-dose HAV vaccine (subgroup analysis)
Number of subjects: 153
Study 37036416 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein (L) supplementation
Number of subjects: 9
Study 37036416 — intervention group
Group type: EXPERIMENTAL
Intervention: Zeaxanthin (Z) supplementation
Number of subjects: 9
Study 37036416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 37036416 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal supplementation starting at E0 or E11
Number of subjects: 9
Study 37036416 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal supplementation starting at P1
Number of subjects: 9
Study 37036495 — intervention group
Group type: EXPERIMENTAL
Intervention: KarXT
Number of subjects: 68
Study 37036495 — intervention group
Group type: COMPARATOR
Intervention: xanomeline alone
Number of subjects: 68
Study 37036495 — intervention group
Group type: EXPERIMENTAL
Intervention: KarXT and xanomeline
Number of subjects: 68
Study 37036495 — intervention group
Group type: EXPERIMENTAL
Intervention: trospium
Number of subjects: 68
Study 37036560 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated subcutaneous immunoglobulin (fSCIG) treatment
Number of subjects: 156
Study 37036671 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8186 (120 mg BID, 5 days on/2 days off) plus paclitaxel (80 mg/m2, days 1, 8, and 15) every 4 weeks
Number of subjects: 18
Study 37036696 — intervention group
Group type: EXPERIMENTAL
Intervention: Decay-Accelerating Factor
Number of subjects: 0
Study 37036721 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching intervention (3 one-on-one sessions, 2 with feedback on audio-recorded encounters)
Number of subjects: 40
Study 37036721 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching intervention
Number of subjects: 40
Study 37036721 — intervention group
Group type: COMPARATOR
Intervention: Control group (no coaching intervention)
Number of subjects: 40
Study 37036722 — intervention group
Group type: EXPERIMENTAL
Intervention: Avalglucosidase alfa (20 mg/kg by intravenous infusion every other week for 49 weeks)
Number of subjects: 100
Study 37036722 — intervention group
Group type: COMPARATOR
Intervention: Avalglucosidase alfa (after switching from alglucosidase alfa)
Number of subjects: 100
Study 37036722 — intervention group
Group type: EXPERIMENTAL
Intervention: Avalglucosidase alfa
Number of subjects: 100
Study 37036722 — intervention group
Group type: COMPARATOR
Intervention: Alglucosidase alfa
Number of subjects: 100
Study 37036756 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole 100 mg PO BID + Sorafenib 400 mg AM/200 mg PM (MTD)
Number of subjects: 35
Study 37036756 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole + Sorafenib
Number of subjects: 35
Study 37036783 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention for pediatric obesity; details on dosage and duration not available.
Number of subjects: 0
Study 37036783 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; details on intervention or control not available.
Number of subjects: 0
Study 37036793 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-Based Buddhist Walking Meditation
Number of subjects: 0
Study 37036793 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37036843 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-coach guided diet and exercise intervention (16 weekly sessions in family home)
Number of subjects: 0
Study 37036843 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-coach guided diet and exercise intervention
Number of subjects: 0
Study 37036890 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based deworming (SBD) reporting
Number of subjects: 0
Study 37036890 — intervention group
Group type: COMPARATOR
Intervention: Control arm (only school-level reporting of SBD coverage)
Number of subjects: 0
Study 37037014 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive stepping intervention
Number of subjects: 0
Study 37037262 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood test as a second-line option
Number of subjects: 359
Study 37037262 — intervention group
Group type: COMPARATOR
Intervention: Control group (colonoscopy/FIT only)
Number of subjects: 359
Study 37037392 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension-focused Clinical Decision Support (CDS) plus practice facilitation
Number of subjects: 46
Study 37037392 — intervention group
Group type: COMPARATOR
Intervention: Clinical Decision Support (CDS) alone
Number of subjects: 46
Study 37037458 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cost standing desk intervention
Number of subjects: 41
Study 37037458 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 41
Study 37037584 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph node yield (LNY) ≥12
Number of subjects: 4575
Study 37037584 — intervention group
Group type: COMPARATOR
Intervention: LNY <12
Number of subjects: 4575
Study 37037585 — intervention group
Group type: EXPERIMENTAL
Intervention: Small tumor-associated macrophages (S-TAMs)
Number of subjects: 84
Study 37037585 — intervention group
Group type: EXPERIMENTAL
Intervention: Large tumor-associated macrophages (L-TAMs)
Number of subjects: 84
Study 37037585 — intervention group
Group type: EXPERIMENTAL
Intervention: TAM area
Number of subjects: 84
Study 37037585 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution of L-TAMs
Number of subjects: 84
Study 37037757 — intervention group
Group type: EXPERIMENTAL
Intervention: XGBoost predictive model
Number of subjects: 369
Study 37037757 — intervention group
Group type: COMPARATOR
Intervention: American Fertility Society (AFS) classification
Number of subjects: 369
Study 37037757 — intervention group
Group type: COMPARATOR
Intervention: Chinese Society for Gynecological Endoscopy (CSGE) classification
Number of subjects: 369
Study 37037757 — intervention group
Group type: COMPARATOR
Intervention: Endometrial thickness
Number of subjects: 369
Study 37037771 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified regional citrate anticoagulation (RCA) protocol for CVVH, CVVHDF and SLED-f
Number of subjects: 47
Study 37037780 — intervention group
Group type: EXPERIMENTAL
Intervention: delgocitinib cream 20 mg/g
Number of subjects: 258
Study 37037780 — intervention group
Group type: COMPARATOR
Intervention: cream vehicle
Number of subjects: 258
Study 37037856 — intervention group
Group type: EXPERIMENTAL
Intervention: Early stoma reversal (within 8-12 days)
Number of subjects: 146
Study 37037856 — intervention group
Group type: COMPARATOR
Intervention: Late stoma reversal (> 3 months)
Number of subjects: 146
Study 37037856 — intervention group
Group type: EXPERIMENTAL
Intervention: Early stoma reversal
Number of subjects: 146
Study 37037856 — intervention group
Group type: COMPARATOR
Intervention: Late stoma reversal
Number of subjects: 146
Study 37037880 — intervention group
Group type: EXPERIMENTAL
Intervention: Door-to-Door
Number of subjects: 2019
Study 37037880 — intervention group
Group type: COMPARATOR
Intervention: Community Health Day
Number of subjects: 2019
Study 37037948 — intervention group
Group type: EXPERIMENTAL
Intervention: Pen-administered low-dose dasiglucagon
Number of subjects: 24
Study 37037948 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study 37037952 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYNOTE-059)
Number of subjects: 34
Study 37037952 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYNOTE-061)
Number of subjects: 34
Study 37037952 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (KEYNOTE-061)
Number of subjects: 34
Study 37037952 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYNOTE-062)
Number of subjects: 34
Study 37037952 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (KEYNOTE-062)
Number of subjects: 34
Study 37038006 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly carboplatin (area under the curve 1.5 mg/ml)
Number of subjects: 0
Study 37038006 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 blockade
Number of subjects: 0
Study 37038005 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab therapy
Number of subjects: 0
Study 37038105 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Self-rehabilitation Contract (GSC) involving daily self-rehabilitation program focusing on three facial muscle groups (Frontalis, Orbicularis oculi, Zygomatici) for six months.
Number of subjects: 82
Study 37038105 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Self-rehabilitation Contract (GSC)
Number of subjects: 82
Study 37038105 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 82
Study 37038126 — intervention group
Group type: EXPERIMENTAL
Intervention: CQI intervention for 18 months including reflective sessions, plan-do-study-act cycles, and group mentoring.
Number of subjects: 48
Study 37038126 — intervention group
Group type: COMPARATOR
Intervention: Audit-feedback report on access (control group).
Number of subjects: 48
Study 37038138 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance after neoadjuvant chemoradiotherapy (nCRT)
Number of subjects: 0
Study 37038138 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemoradiotherapy (nCRT) followed by esophagectomy
Number of subjects: 0
Study 37038146 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous online pain science education
Number of subjects: 0
Study 37038146 — intervention group
Group type: EXPERIMENTAL
Intervention: Asynchronous videos pain science education
Number of subjects: 0
Study 37038146 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive e-book pain science education
Number of subjects: 0
Study 37038159 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg (UPA15)
Number of subjects: 0
Study 37038159 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 37038159 — intervention group
Group type: COMPARATOR
Intervention: adalimumab 40 mg (ADA)
Number of subjects: 0
Study 37038176 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Childbirth and Parenting (MBCP) intervention
Number of subjects: 80
Study 37038176 — intervention group
Group type: COMPARATOR
Intervention: Active control treatment
Number of subjects: 80
Study 37038216 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells (MSCs) embedded in tricalcium phosphate
Number of subjects: 11
Study 37038235 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS for Navigating Pain (COMPASS-NP)
Number of subjects: 140
Study 37038235 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 140
Study 37038637 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37038736 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37038819 — intervention group
Group type: EXPERIMENTAL
Intervention: QDRS Total score after one year follow-up
Number of subjects: 110
Study 37038819 — intervention group
Group type: EXPERIMENTAL
Intervention: QDRS Total score after one year follow-up in MCI subjects
Number of subjects: 110
Study 37038819 — intervention group
Group type: EXPERIMENTAL
Intervention: QDRS Total score after one year follow-up in mild AD subjects
Number of subjects: 110
Study 37038819 — intervention group
Group type: EXPERIMENTAL
Intervention: QDRS Total score after one year follow-up in intact subjects
Number of subjects: 110
Study 37038819 — intervention group
Group type: EXPERIMENTAL
Intervention: QDRS Total score after one year follow-up in amyloid positive subjects
Number of subjects: 110
Study 37038819 — intervention group
Group type: EXPERIMENTAL
Intervention: QDRS Total score after one year follow-up in amyloid negative subjects
Number of subjects: 110
Study 37038875 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 121
Study 37038875 — intervention group
Group type: EXPERIMENTAL
Intervention: GWW ≥200 mm Hg%
Number of subjects: 121
Study 37038875 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal strain septal contraction patterns 1 and 2
Number of subjects: 121
Study 37038875 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive criteria for echocardiographic assessment of EMD
Number of subjects: 121
Study 37038875 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of either of the 2 criteria
Number of subjects: 121
Study 37038897 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13 (Inflectra®)
Number of subjects: 2543
Study 37038897 — intervention group
Group type: COMPARATOR
Intervention: Reference infliximab (IFX; Remicade®)
Number of subjects: 2543
Study 37038980 — intervention group
Group type: EXPERIMENTAL
Intervention: PAPP-A blood level measurement
Number of subjects: 0
Study 37038980 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 0
Study 37038986 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation stent placement with 125 I plus TACE (ISP-TACE)
Number of subjects: 105
Study 37038986 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib plus TACE (Sora-TACE)
Number of subjects: 105
Study 37039013 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigenetic age acceleration (EAA) group (n=188)
Number of subjects: 2502
Study 37039013 — intervention group
Group type: COMPARATOR
Intervention: Epigenetic age deceleration (EAD) group (n=195)
Number of subjects: 2502
Study 37039013 — intervention group
Group type: EXPERIMENTAL
Intervention: EAA group (n=188)
Number of subjects: 2502
Study 37039015 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 3048
Study 37039015 — intervention group
Group type: COMPARATOR
Intervention: Higher baseline ET-1 concentration
Number of subjects: 3048
Study 37039068 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth integration for alcohol-focused services
Number of subjects: 18
Study 37039068 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural adaptations in telehealth services
Number of subjects: 18
Study 37039068 — intervention group
Group type: EXPERIMENTAL
Intervention: Common workflows for referring clients to treatment
Number of subjects: 18
Study 37039068 — intervention group
Group type: EXPERIMENTAL
Intervention: Research workflows and staff involvement
Number of subjects: 18
Study 37039338 — intervention group
Group type: EXPERIMENTAL
Intervention: Extemporaneously compounded enteral caffeine base solution
Number of subjects: 0
Study 37039393 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants on a PIM at baseline
Number of subjects: 19114
Study 37039393 — intervention group
Group type: EXPERIMENTAL
Intervention: PIMs exposure
Number of subjects: 19114
Study 37039393 — intervention group
Group type: EXPERIMENTAL
Intervention: PPIs, anti-psychotics, and benzodiazepines
Number of subjects: 19114
Study 37039536 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarticular drilling (TAD)
Number of subjects: 91
Study 37039536 — intervention group
Group type: COMPARATOR
Intervention: Retroarticular drilling (RAD)
Number of subjects: 91
Study 37039792 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 270
Study 37039792 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 270
Study 37039792 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 270
Study 37039792 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 270
Study 37039792 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized treatment
Number of subjects: 270
Study 37039792 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril vs Hydrochlorothiazide
Number of subjects: 270
Study 37039792 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril vs Amlodipine
Number of subjects: 270
Study 37039792 — intervention group
Group type: COMPARATOR
Intervention: Candesartan vs Hydrochlorothiazide
Number of subjects: 270
Study 37039792 — intervention group
Group type: COMPARATOR
Intervention: Candesartan vs Amlodipine
Number of subjects: 270
Study 37039792 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril vs Candesartan
Number of subjects: 270
Study 37039792 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide vs Amlodipine
Number of subjects: 270
Study 37039791 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA-127 (0.5-mg/kg intravenous infusion once daily for 5 days)
Number of subjects: 343
Study 37039791 — intervention group
Group type: EXPERIMENTAL
Intervention: TRV-027 (12-mg/h continuous intravenous infusion for 5 days)
Number of subjects: 343
Study 37039791 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for both trials)
Number of subjects: 343
Study 37039805 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopy (n=288)
Number of subjects: 574